Estrella Immunopharma
ESLA
10 hedge funds and large institutions have $232K invested in Estrella Immunopharma in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
80% more capital invested
Capital invested by funds: $129K → $232K (+$103K)
43% more funds holding
Funds holding: 7 → 10 (+3)
0.21% more ownership
Funds ownership: 0.34% → 0.55% (+0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$23.6K |
| 3 |
BlackRock
New York
|
+$22.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$18.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.83K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $88.8K | +$23.6K | +18,342 | +32% |
|
|
ASM
2
ATW SPAC Management
New York
| $46.4K | – | – | – |
|
|
3
BlackRock
New York
| $29K | +$22.4K | +17,395 | +230% |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $25.2K | +$27.9K | +21,684 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| $16.9K | +$18.7K | +14,531 | New |
|
|
MCP
6
Maso Capital Partners
Hong Kong
| $11.6K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $7.57K | +$8.39K | +6,523 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $6.64K | -$1.83K | -1,423 | -20% |
|
9
Bank of America
Charlotte,
North Carolina
| $96 | +$6 | +5 | +6% |
|
10
JP Morgan Chase
New York
| $31 | +$1 | +1 | +4% |
|
ESLA Hedge Fund Activity: Q3 2024 in Review
10 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q3 2024, worth a combined $232K — up 80% from $129K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ESLA positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $27.9K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.83K.
- 10 institutional investors held Estrella Immunopharma (ESLA) as of Q3 2024, up from 7 in Q2 2024.
- Funds reported $232K of Estrella Immunopharma stock for Q3 2024, up 80% quarter-over-quarter.
- 3 funds opened new Estrella Immunopharma positions in Q3 2024 and 0 closed out, a net change of +3 holders.
- The largest Estrella Immunopharma buyer in Q3 2024 was Vanguard Group, an estimated $27.9K added.
- The largest Estrella Immunopharma seller in Q3 2024 was Tower Research Capital (TRC), an estimated $1.83K sold.
Based on aggregated 13F filings for Q3 2024.